跳转至内容
Merck

38956

Supelco

辛伐他汀

analytical standard

登录查看公司和协议定价

选择尺寸

10 MG
$178.00

$178.00


请联系客服了解存货情况

获取大包装报价

选择尺寸

变更视图
10 MG
$178.00

About This Item

经验公式(希尔记法):
C25H38O5
CAS号:
分子量:
418.57
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

$178.00


请联系客服了解存货情况

获取大包装报价

等级

analytical standard

质量水平

方案

≥98.0% (HPLC)

旋光性

[α]/D +275±25°, c = 1 in acetonitrile

保质期

limited shelf life, expiry date on the label

技术

HPLC: suitable
gas chromatography (GC): suitable

杂质

≤0.5% water

mp

127-132 °C (lit.)

应用

forensics and toxicology
pharmaceutical (small molecule)
veterinary

包装形式

neat

储存温度

2-8°C

SMILES字符串

[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC

InChI

1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

InChI key

RYMZZMVNJRMUDD-HGQWONQESA-N

基因信息

human ... HMGCR(3156)

正在寻找类似产品? 访问 产品对比指南

应用

有关合适仪器技术的更多信息,请参考产品分析证书。如需进一步支持,请联系技术服务。

生化/生理作用

辛伐他汀是HMG-CoA还原酶和降胆固醇药物的特异性抑制剂。
辛伐他汀是HMG-CoA还原酶的特异性抑制剂,HMG-CoA还原酶是催化HMG-CoA转化为甲羟戊酸的酶,其是胆固醇生物合成的早期步骤。由于它可以降低低密度脂蛋白和甘油三酯的水平,并提高高密度脂蛋白水平,因而可用于治疗高胆固醇血症。辛伐他汀是一种内酯,其在体内 易于水解成相应的β-羟基酸,并可以在使用前用溶于EtOH中的NaOH进行活化。它是洛伐他汀的合成类似物(货M2147)。

象形图

Health hazard

警示用语:

Warning

危险声明

危险分类

Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Joost Besseling et al.
JAMA, 313(10), 1029-1036 (2015-03-11)
Familial hypercholesterolemia is characterized by impaired uptake of cholesterol in peripheral tissues, including the liver and the pancreas. In contrast, statins increase the cellular cholesterol uptake and are associated with increased risk for type 2 diabetes mellitus. We hypothesize that
Peter J Kirkpatrick et al.
The Lancet. Neurology, 13(7), 666-675 (2014-05-20)
The benefit of statins in patients with acute aneurysmal subarachnoid haemorrhage is unclear. We aimed to determine whether simvastatin 40 mg could improve the long-term outcome in patients with this disorder. In this international, multicentre, randomised, double-blind trial, we enrolled
Jennifer G Robinson et al.
JAMA, 311(18), 1870-1882 (2014-05-16)
In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin. Phase 3
Laura Marin et al.
Expert opinion on drug delivery, 8(9), 1205-1220 (2011-05-28)
Chronic Obstructive Pulmonary Disease (COPD) is a severe disease that leads to a non-reversible obstruction of the small airways. The prevalence of this disease is rapidly increasing in developed countries, and in 2020 it has been predicted that this disease
L B Ramsey et al.
Clinical pharmacology and therapeutics, 96(4), 423-428 (2014-06-12)
Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门